Alduaij W et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011;117(17):4519-29. Abstract

Armand P et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 2018;36(14):1428-39. Abstract

Barf T et al. Acalabrutinib (ACP-196): A covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther 2017;363(2):240-52. Abstract

Castellino A et al. High efficacy of lenalidomide plus R-CHOP (R2CHOP) combination in first line treatment of activated B-cell (ABC) DLBCL defined using gene-expression prophyling: A combined analysis from two phase 2 trials. Proc ASH 2018;Abstract 2962.

Castellino A et al. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): Long-term follow-up results from a combined analysis from two phase 2 trials. Blood Cancer J 2018;8(11):108. Abstract

Chen R et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35(19):2125-32. Abstract

Connors JM et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med 2018;378(4):331-44. Abstract

Davids MS et al. Long-term follow-up of patients with mantle cell lymphoma treated with venetoclax monotherapy. Proc ASH 2018;Abstract 2883.

Davids MS et al. Revised dose ramp-up to mitigate the risk of tumor lysis syndrome when initiating venetoclax in patients with mantle cell lymphoma. J Clin Oncol 2018;36(35):3525-7. Abstract

Davids MS, Letai A. ABT-199: Taking dead aim at BCL-2. Cancer Cell 2013;23(2):139-41. Abstract

Davies A et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): A randomised, open-label, phase 3 trial. Lancet Oncol 2017;4(6):e272-e82. Abstract

Dreyling M et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol 2017;35(35):3898-905. Abstract

Flinn IW et al. DYNAMO: A phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol 2019;37(11):912-22. Abstract

Gopal AK et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370(11):1008-18. Abstract

Jain P et al. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol 2018;182(3):404-11. Abstract

Lampson BL, Brown JR. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs 2017;26(11):1267-79. Abstract

Le Gouill S et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med 2017;377(13):1250-60. Abstract

Leonard JP et al. De-cell-eration in therapy for diffuse large B-cell lymphoma. J Clin Oncol 2019;[Epub ahead of print]. Abstract

Marcus R et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 2017;377(14):1331-44. Abstract

Morschhauser F et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 2018;379(10):934-47. Abstract

Morschhauser F et al. Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients with relapsed/refractory non-Hodgkin lymphoma. Proc ASCO 2014;Abstract 8519.

Moskowitz CH et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood 2018;132(25):2639-42. Abstract

Moskowitz CH et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;385(9980):1853-62. Abstract

Mössner E et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115(22):4393-402. Abstract

Neelapu SS et al. Chimeric antigen receptor T-cell therapy — Assessment and management of toxicities. Nat Rev Clin Oncol 2018;15(1):47-62. Abstract

Niederfellner G et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011;118(2):358-67. Abstract

Ramchandren R et al. Brentuximab vedotin plus chemotherapy in North American subjects with newly diagnosed stage III or IV Hodgkin lymphoma. Clin Cancer Res 2019;25(6):1718-26. Abstract

Roemer MGM et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 2016;34(23):2690-7. Abstract

Ruan J et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood 2018;132(19):2016-25. Abstract

Sehn LH et al. Polatuzumab vedotin (Pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Updated results of a phase (Ph) Ib/II study. Proc ASH 2018;Abstract 1683.

Sehn LH et al. Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. Proc ASCO 2018;Abstract 7507.

Sweetenham J et al. Updated efficacy and safety data from the AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse. Proc ASH 2015;Abstract 3172.

Townsend W et al. Obinutuzumab-based immunochemotherapy prolongs progression-free survival and time to next anti-lymphoma treatment in patients with previously untreated follicular lymphoma: Four-year results from the phase III GALLIUM study. Proc ASH 2018;Abstract 1597.

Trněný M et al. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): A phase 2, randomised, multicentre trial. Lancet Oncol 2016;17(3):319-31. Abstract

Villasboas JC, Ansell SA. Checkpoint inhibition: Programmed cell death 1 and programmed cell death 1 ligand inhibitors in Hodgkin lymphoma. Cancer J 2016;22(1):17-22. Abstract

Wang M et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicentre, phase 2 trial. Lancet 2018;391(10121):659-67. Abstract

Woyach JA et al. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012;120(6):1175-84. Abstract